201 related articles for article (PubMed ID: 19954746)
1. Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response.
Yadav SS; Ruwali M; Pant MC; Shukla P; Singh RL; Parmar D
Mutat Res; 2010 Feb; 684(1-2):49-55. PubMed ID: 19954746
[TBL] [Abstract][Full Text] [Related]
2. Association of poor metabolizers of cytochrome P450 2C19 with head and neck cancer and poor treatment response.
Yadav SS; Ruwali M; Shah PP; Mathur N; Singh RL; Pant MC; Parmar D
Mutat Res; 2008 Sep; 644(1-2):31-7. PubMed ID: 18644391
[TBL] [Abstract][Full Text] [Related]
3. Association and treatment response to capecitabine-based chemoradiotherapy with CYP2C9 polymorphism in head and neck cancer.
Paul S; Pant MC; Parmar D; Verma J
Indian J Cancer; 2011; 48(2):223-9. PubMed ID: 21768671
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome.
Ruwali M; Pant MC; Shah PP; Mishra BN; Parmar D
Mutat Res; 2009 Oct; 669(1-2):36-41. PubMed ID: 19406142
[TBL] [Abstract][Full Text] [Related]
5. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in drug-metabolizing enzymes and risk to head and neck cancer: evidence for gene-gene and gene-environment interaction.
Maurya SS; Anand G; Dhawan A; Khan AJ; Jain SK; Pant MC; Parmar D
Environ Mol Mutagen; 2014 Mar; 55(2):134-44. PubMed ID: 24519899
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
Naujokaitis D; Asmoniene V; Kadusevicius E
Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
[TBL] [Abstract][Full Text] [Related]
10. CYP 2D6 polymorphism: a predictor of susceptibility and response to chemoradiotherapy in head and neck cancer.
Shukla P; Gupta D; Pant MC; Parmar D
J Cancer Res Ther; 2012; 8(1):40-5. PubMed ID: 22531512
[TBL] [Abstract][Full Text] [Related]
11. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
[TBL] [Abstract][Full Text] [Related]
12. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
Kirchheiner J; Müller G; Meineke I; Wernecke KD; Roots I; Brockmöller J
J Clin Psychopharmacol; 2003 Oct; 23(5):459-66. PubMed ID: 14520122
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
[TBL] [Abstract][Full Text] [Related]
14. Association of polymorphism in cytochrome P450 2C9 with susceptibility to head and neck cancer and treatment outcome.
Yadav SS; Seth S; Khan AJ; Maurya SS; Dhawan A; Pant S; Pant MC; Parmar D
Appl Transl Genom; 2014 Mar; 3(1):8-13. PubMed ID: 27275407
[TBL] [Abstract][Full Text] [Related]
15. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.
Serrano D; Lazzeroni M; Zambon CF; Macis D; Maisonneuve P; Johansson H; Guerrieri-Gonzaga A; Plebani M; Basso D; Gjerde J; Mellgren G; Rotmensz N; Decensi A; Bonanni B
Pharmacogenomics J; 2011 Apr; 11(2):100-7. PubMed ID: 20309015
[TBL] [Abstract][Full Text] [Related]
17. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
18. Gene polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer?
Gronau S; Koenig-Greger D; Jerg M; Riechelmann H
Otolaryngol Head Neck Surg; 2003 May; 128(5):674-80. PubMed ID: 12748560
[TBL] [Abstract][Full Text] [Related]
19. Poor metabolizer status at the cytochrome P450 2C9 and 2D6 loci does not modulate susceptibility to therapy-related acute myeloid leukaemia.
Roddam PL; Allan JM; Rollinson S; Smith AG; Willett EV; Swirsky D; Roman E; Morgan GJ
Br J Haematol; 2003 Apr; 121(1):192-4. PubMed ID: 12670355
[No Abstract] [Full Text] [Related]
20. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.
de Leon J; Armstrong SC; Cozza KL
Psychosomatics; 2006; 47(1):75-85. PubMed ID: 16384813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
